Higher levels of cystatin C are associated with worse cognitive function in older adults with chronic kidney disease: The chronic renal insufficiency cohort cognitive study

Journal of the American Geriatrics Society

Volumn 62, Issue 9, 2014, Pages 1623-1629

  Yaffe, Kristine ^a,b   Kurella Tamura, Manjula ^c,d   Ackerson, Lynn ^e   Hoang, Tina D ^a   Anderson, Amanda H ^g   Duckworth, Mark ^g   Go, Alan S ^e,f   Krousel Wood, Marie ^h,i,j   Kusek, John W ^k   Lash, James P ^l   Ojo, Akinlolu ^m   Robinson, Nancy ^g   Sehgal, Ashwini R ^n,o   Sondheimer, James H ^p   Steigerwalt, Susan ^q   Townsend, Raymond R ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e DIVISION OF RESEARCH   (United States)

^f Northern California Geriatric Education Center   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ TULANE UNIVERSITY   (United States)

^j OCHSNER CLINIC FOUNDATION   (United States)

^k NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^l UNIVERSITY OF ILLINOIS   (United States)

^m UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁿ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o CASE WESTERN RESERVE UNIVERSITY   (United States)

^p WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

more..

Author keywords

chronic kidney disease; cognition; cystatin C

Indexed keywords

CYSTATIN C; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CAUCASIAN; CHRONIC KIDNEY DISEASE; COGNITION ASSESSMENT; COGNITIVE DEFECT; COMORBIDITY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSYCHOLOGIC TEST; RACE; BLOOD; COGNITION DISORDERS; EPIDEMIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

AGED; BIOLOGICAL MARKERS; COGNITION DISORDERS; CYSTATIN C; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84921656528     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12986     Document Type: Article

References (48)

1. Kaeser SA, Herzig MC, Coomaraswamy J, et al. Cystatin C modulates cerebral [beta]-amyloidosis. Nat Genet 2007; 39: 1437-1439.
2. Kaur G, Levy E,. Cystatin C in Alzheimer's disease. Front Mol Neurosci 2012; 5: 79.
3. Bugnicourt J-M, Godefroy O, Chillon J-M, et al. Cognitive disorders and dementia in CKD: The neglected kidney-brain axis. J Am Soc Nephrol 2013; 24: 353-363.
4. Sarnak MJ, Katz R, Fried LF, et al. Cystatin C and aging success. Arch Intern Med 2008; 168: 147-153.
5. Yaffe K, Lindquist K, Shlipak MG, et al. Cystatin-C as a marker of cognitive function in elders: Findings from the Health ABC Study. Ann Neurol 2008; 63: 798-802.
6. Sundelof J, Arnlov J, Ingelsson E, et al. Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 2008; 71: 1072-1079.
7. Maetzler W, Schmid B, Synofzik M, et al. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 2010; 19: 937-942.
8. Cathcart HM, Huang R, Lanham IS, et al. Cystatin C as a risk factor for Alzheimer disease. Neurology 2005; 64: 755-757.
9. Finckh U, von der Kammer H, Velden J, et al. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol 2000; 57: 1579-1583.
10. Hua Y, Zhao H, Lu X, et al. Meta-Analysis of the cystatin C (CST3) gene G73A Polymorphism and susceptibility to Alzheimer's disease. Int J Neurosci 2012; 122: 431-438.
11. Deng A, Irizarry MC, Nitsch RM, et al. Elevation of Cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol 2001; 159: 1061-1068.
12. Levy EP, Sastre MP, Kumar AP, et al. Codeposition of cystatin C with amyloid-[beta] protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001; 60: 94-104.
13. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
14. Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147: 19-27.
15. Tangri N, Inker LA, Tighiouart H, et al. Filtration markers may have prognostic value independent of glomerular filtration rate. J Am Soc Nephrol 2012; 23: 351-359.
16. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246.
17. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
18. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305: 1545-1552.
19. Bhavsar NA, Appel LJ, Kusek JW, et al. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis 2011; 58: 886-893.
20. Kurella M, Chertow GM, Fried LF, et al. Chronic kidney disease and cognitive impairment in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 2005; 16: 2127-2133.
21. Kurella M, Chertow GM, Luan J, et al. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004; 52: 1863-1869.
22. Kurella M, Yaffe K, Shlipak MG, et al. Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis 2005; 45: 66-76.
23. Feldman HI, Appel LJ, Chertow GM, et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 2003; 14: S148-S153.
24. Yaffe K, Ackerson L, Tamura MK, et al. Chronic kidney disease and cognitive function in older adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study. J Am Geriatr Soc 2010; 58: 338-345.
25. Erlandsen EJ, Randers E, Kristensen JH,. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999; 59: 1-8.
26. Anderson A, Xie D, Tao K, et al. Internal standardization of cystatin C measurements in the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 2010; 21: 176A. ASN abstract 287.
27. Teng EL, Chui HC,. The modified Mini-Mental State (3MS) Examination. J Clin Psychiatry 1987; 48: 314-318.
28. Reitan RM,. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271-276.
29. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994; 44: 609-614.
30. Buschke H, Fuld PA,. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24: 1019-1025.
31. Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920-929.
32. Seliger SL, Siscovick DS, Stehman-Breen CO, et al. Moderate renal impairment and risk of dementia among older adults: The Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004; 15: 1904-1911.
33. Slinin Y, Paudel ML, Ishani A, et al. Kidney function and cognitive performance and decline in older men. J Am Geriatr Soc 2008; 56: 2082-2088.
34. Tamura MK, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Kidney Dis 2008; 52: 227-234.
35. Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005; 16: 3721-3727.
36. Wada M, Nagasawa H, Kawanami T, et al. Cystatin C as an index of cerebral small vessel disease: Results of a cross-sectional study in community-based Japanese elderly. Eur J Neurol 2010; 17: 383-390.
37. Rajagopalan P, Refsum H, Hua X, et al. Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. Neurobiol Aging 2013; 34: 1221-1230.
38. Smith EE, Salat DH, Jeng J, et al. Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology 2011; 76: 1492-1499.
39. Ghidoni R, Benussi L, Glionna M, et al. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J Alzheimers Dis 2010; 22: 985-991.
40. Kestenbaum B, Rudser KD, de Boer IH, et al. Differences in kidney function and incident hypertension: The Multi-Ethnic Study of Atherosclerosis. Ann Intern Med 2008; 148: 501-508.
41. Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008; 121: 341-348.
42. Gr Luc, Bard J-M, Cl Lesueur, et al. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis 2006; 185: 375-380.
43. Sundelof J, Sundstrom J, Hansson O, et al. Cystatin C levels are positively correlated with both a-beta 42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 2010; 21: 471-478.
44. Sun B, Zhou Y, Halabisky B, et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 2008; 60: 247-257.
45. Tizon B, Ribe EM, Mi W, et al. Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 2010; 19: 885-894.
46. Sastre M, Calero M, Pawlik M, et al. Binding of cystatin C to Alzheimer's amyloid β inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004; 25: 1033-1043.
47. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 2006; 17: 254-261.
48. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22: 147-155.